Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Chemistry (Weinheim an der Bergstrasse, Germany). 2019 Sep 27. doi: 10.1002/chem.201903605
    The first anticancer tris(pyrazolyl)borate molybdenum(IV) complexes: tested in vitro and in vivo - a comparison of O,O-, S,O-, and N,N-chelate effects.
    Berasaluce I1,  Cseh K2,  Roller A3,  Hejl M4,  Heffeter P5,  Berger W6,  Jakupec MA7,  Kandioller W8,  Malarek MS9,  Keppler BK10
    Author information
    1Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    2Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    3Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    4Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    5Research Cluster 'Translational Cancer Therapy Research', University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090, Vienna, Aust, AUSTRIA.
    6Research Cluster 'Translational Cancer Therapy Research', University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, A-1090, Vienna, Aust, AUSTRIA.
    7Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. Research Cluster 'Translational Cancer Therapy Research', University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    8Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. Research Cluster 'Translational Cancer Therapy Research', University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    9Universitat Wien, Institute of Inorganic Chemistry, Währinger Straße 42, 1090, Vienna, AUSTRIA.
    10Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria. Research Cluster 'Translational Cancer Therapy Research', University of Vienna, Waehringer Straße 42, A-1090 Vienna, Austria, AUSTRIA.
    Abstract

    The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3-isopropylpyrazolyl)borate (TpiPr), in addition to varying biologically active as well as other conventional ligands is described. Ligands employed include (O,O-) (S,O-) (N,N-) donors which have been successfully coordinated to the molybdenum center by means of oxygen-atom transfer (OAT) reactions from the known MoVI starting material, TpiPrMoO2Cl. The synthesized complexes were characterized by standard analytical methods, and where possible by X-ray diffraction analysis. The aqueous stability of the compounds was studied by means of UV/Vis spectroscopy and the impact of the attached ligand scaffolds on the oxidation potentials (MoIV to MoV) was studied by cyclic voltammetry. Utilizing polyvinylpyrrolidone (PVP) as a solubilizing agent, adequate aqueous solubility for biological tests was obtained. The anticancer activity and preliminary mode of action studies have been performed in vitro and in vivo.


    © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

    KEYWORDS: anticancer, biological tests, in vivo experiments, molybdenum, tris(pyrazolyl)borate

    Publikations ID: 31560142
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt